Sex Differences in Cardiometabolic Health and Disease

心脏代谢健康和疾病的性别差异

基本信息

批准号：
10713757
负责人：
Karen Reue
金额：
$ 149.76万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-20 至 2028-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10713757
关键词：
Adverse effects Bioinformatics Biological Biological Models Cardiac Cardiac Myocytes Cardiometabolic Disease Cardiomyopathies Cardiotoxicity Cardiovascular Diseases Cell Line Collaborations Communication Computer Analysis Coronary Coronary Arteriosclerosis Coronary artery Data Data Set Dedications Development Diagnosis Disease Dissection EFRAC Ensure Enzymes Epigenetic Process Estrogen Receptor alpha Estrogen Receptors Estrogens Experimental Models Female Fostering Genes Genetic Genetic Variation Genomics Goals Gonadal Hormones Grant Health Heart failure Hormones Human Human Genetics Individual Investigation Knock-out Laboratories Leadership Libraries Metabolism Microvascular Dysfunction Mitochondria Molecular Mouse Strains Mus Mutation Myocardial Infarction Obesity Operations Research Patients Pharmaceutical Preparations Population Predisposition Prevalence Prevention Preventive Process Proteomics Publishing Research Research Personnel Research Project Grants Risk Role Series Sex Bias Sex Chromosomes Sex Differences Stress cardiomyopathy Stroke Students System Testing Tissues Translating Woman Y Chromosome adipocyte differentiation cardiometabolism career cell type diet-induced obesity disorder risk epigenetic regulation genetic approach heart function histone demethylase human data human model improved induced pluripotent stem cell insight knock-down meetings men metabolomics mitochondrial dysfunction mitochondrial metabolism mortality mouse model overexpression pre-clinical preservation programs response sex symposium therapeutic development therapy development trait transcriptomics

项目摘要

Overall SUMMARY The objective of our SCORE on “Sex Differences in Cardiometabolic Health and Disease” is to identify factors that determine sex-specific cardiometabolic disease risk, which may lead to better diagnosis and treatment for both sexes. A unique feature of our program is the investigation of sex differences from multiple perspectives, including effects of estrogen, of XX vs. XY sex chromosome genes, and of genetic variation among individuals. Our program consists of three research projects and three cores, and will use preclinical mouse models, human induced pluripotent stem cell lines (iPSCs), and existing human population datasets (genomic, transcriptomic, proteomic, and metabolomic) to translate findings from our model systems to humans. Project 1, “Epigenetic sex determinants of cardiometabolic disease and prevention,” will build on our identification of X and Y chromosome genes that influence sex differences in both the development of diet- induced obesity and susceptibility to adverse effects of statin drugs. We will elucidate the role of three X-Y histone demethylase genes in epigenetic sex differences in mouse adiposity and human adipocyte differentiation. We will also identify the epigenetic determinants of sex-biased statin adverse effects on mitochondrial function. Project 2, “Gene-by-sex interactions in heart failure with preserved ejection fraction (HFpEF),” seeks to understand the mechanisms underlying increased prevalence of HFpEF in women compared to men. Using a “systems genetics” approach and a panel of genetically distinct mouse strains, the goals are to understand sex differences in HFpEF traits at the molecular level, including the role of gonadal hormones and sex chromosomes, and to create sex-specific biologic networks that can be generalized to humans. Recent findings implicate sex differences in the mitochondrial enzyme, ACSL6, as causal for HFpEF, and further studies will characterize the role of mitochondrial dysfunction in HFpEF. Project 3, “The impact of estrogen receptor alpha on cardiomyocellular metabolism and health,” will test the hypothesis that estrogen receptor alpha action in cardiomyocytes impacts mitochondrial metabolism, cardiac tissue integrity and heart function. Findings with unique cardiomyocyte estrogen receptor alpha knockout or overexpression mouse models will then be integrated with human data in collaboration with our Human Translational Bioinformatics Core. The Human Translational Bioinformatics Core will serve as hub for computational analyses to translate findings from the three Projects for association and relevant to cardiometabolic traits in humans using existing large human genetic and –omics datasets. The Career Enhancement Core will foster research in sex differences in metabolism by administering a Pilot & Feasibility grant program, and will educate researchers and students about SABV through courses, hands-on laboratory ‘bootcamp,’ and a library of SABV videos. The Administrative Core will ensure effective leadership and management of this SCORE.

全面的概括我们关于“心脏代谢健康和疾病的性别差异”的 SCORE 的目标是确定决定性别特异性心脏代谢疾病风险的因素，这可能会导致更好的诊断和我们项目的一个独特之处是调查多个性别的差异。观点，包括雌激素、XX 与 XY 性染色体基因以及遗传变异的影响我们的计划由三个研究项目和三个核心组成，并将使用临床前研究。小鼠模型、人类诱导多能干细胞系 (iPSC) 和现有人群数据集（基因组学、转录组学、蛋白质组学和代谢组学）将我们模型系统的发现转化为项目 1“心脏代谢疾病的表观遗传性别决定因素及其预防”将建立在我们的基础上。鉴定影响饮食发展中性别差异的 X 和 Y 染色体基因我们将阐明三个X-Y的作用。组蛋白去甲基化酶基因在小鼠肥胖和人类脂肪细胞表观遗传性别差异中的作用我们还将确定性别偏见的他汀类药物不良反应的表观遗传决定因素。线粒体功能。项目 2，“射血分数保留的心力衰竭中的基因与性别的相互作用” (HFpEF)”，旨在了解女性 HFpEF 患病率增加的机制与男性相比，使用“系统遗传学”方法和一组基因不同的小鼠品系，目标是在分子水平上了解 HFpEF 特征的性别差异，包括性腺的作用激素和性染色体，并创建可推广到的性别特异性生物网络最近的研究结果表明线粒体酶 ACSL6 的性别差异是 HFpEF 的原因，进一步的研究将描述线粒体功能障碍在 HFpEF 中的作用，项目 3“线粒体功能障碍的影响”。雌激素受体α对心肌细胞代谢和健康的影响，”将检验雌激素的假设心肌细胞中受体α的作用影响线粒体代谢、心脏组织完整性和心脏独特的心肌细胞雌激素受体α敲除或过度表达小鼠的发现。然后，模型将与我们的人类转化生物信息学合作与人类数据集成人类翻译生物信息学核心将作为计算分析的中心将三个项目的研究结果转化为与人类心脏代谢特征的关联和相关性现有的大型人类遗传和组学数据集将促进性研究。通过管理试点和可行性资助计划来研究新陈代谢的差异，并将教育研究人员学生通过课程、实验室“训练营”和 SABV 视频库了解 SABV。行政核心将确保对该 SCORE 的有效领导和管理。